中文 | English
Return
Total: 4 , 1/1
Show Home Prev Next End page: GO
Author:(Hsiang-Hsuan SUNG)

1.Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.

Jeng Sen TSENG ; Tsung Ying YANG ; Kun Chieh CHEN ; Kuo Hsuan HSU ; Yen Hsiang HUANG ; Kang Yi SU ; Sung Liang YU ; Gee Chen CHANG

Cancer Research and Treatment 2018;50(4):1164-1174

2.Refined protocol for newly onset identification in non-obese diabetic mice: an animal-friendly, cost-effective, and efficient alternative

Chia-Chi LIAO ; Chia-Chun HSIEH ; Wei-Chung SHIA ; Min-Yuan CHOU ; Chuan-Chuan HUANG ; Jhih-Hong LIN ; Shu-Hsien LEE ; Hsiang-Hsuan SUNG

Laboratory Animal Research 2024;40(2):269-279

3.The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

Yen-Hsiang HUANG ; Kuo-Hsuan HSU ; Chun-Shih CHIN ; Jeng-Sen TSENG ; Tsung-Ying YANG ; Kun-Chieh CHEN ; Kang-Yi SU ; Sung-Liang YU ; Jeremy J.W. CHEN ; Gee-Chen CHANG

Cancer Research and Treatment 2022;54(2):434-444

4.The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.

Yen Hsiang HUANG ; Kuo Hsuan HSU ; Jeng Sen TSENG ; Kun Chieh CHEN ; Chia Hung HSU ; Kang Yi SU ; Jeremy J W CHEN ; Huei Wen CHEN ; Sung Liang YU ; Tsung Ying YANG ; Gee Chen CHANG

Cancer Research and Treatment 2018;50(4):1294-1303

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 4 , 1/1 Show Home Prev Next End page: GO